Biotechnology
Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China
* Collaboration to accelerate the development and access of oncology medicines for cancer patients inChina * Clinical trial programs combining two of Sanofi's prioritized oncology assets with sintilimab, the leading checkpoint inhibitor inChina, to address some of the most prevalent solid tum...
2022-08-04 23:30
3795
MGI Announces Commercial Availability of HotMPS Sequencing Chemistry*and Instrument**in the United Kingdom
SHENZHEN, China, July 28, 2022 /PRNewswire/ -- MGI Tech (MGI) announced that its innovative HotMPS sequencing chemistry* and instrument** are commercially available in theUnited Kingdom, from 23rd June 2022. Further details will be communicated during the 17th Annual Meeting of the International ...
2022-08-04 22:50
2439
Genesis Capital invests in Crux Biolabs, a leading bioanalytical laboratory to the clinical trials sector
* Crux Biolabs is a decade-old Australian leader in bioanalytics, customised biomarker detection, cell assay development, clinical and pre-clinical testing with particular strength in the immuno-oncology clinical trials market * Genesis Capital is partnering with existing management to expand ...
2022-08-04 22:01
3098
CGBio Signing a North America Out-license Contract on "Novosis rhBMP-2," a Bone Substitute with Orthofix, USA
* Embarking on a successful journey of exporting its home-grown product technology toNorth America, the largest market for bone substitutes * Enabling fast bone formation by applying bone morphogenetic protein (rhBMP-2) and next-generation synthetic carrier SEOUL, South Korea and LEWISVILLE, ...
2022-08-04 21:00
2163
RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB
* Radiopharm will shortly initiate a PD-L1 Phase 1 therapeutic study in Australia in patients with NSCLC * Radiopharm acquired from NanoMab, Ltd. worldwide rights to PD-L1 technology for therapeutic use, as well as to imaging rights inChina MELBOURNE, Australia, Aug. 3, 2022 /PRNewswire/ -- R...
2022-08-04 10:15
1384
Firmenich Appoints Maurizio Clementi ad interim President of its Taste & Beyond Division
GENEVA, Aug. 3, 2022 /PRNewswire/ -- Firmenich, the world's largest privately-owned fragrance and taste company, is pleased to announce the appointment ofMaurizio Clementi as ad interim President of its Taste & Beyond division, effective immediately. This move follows former PresidentEmmanuel Bu...
2022-08-03 20:57
2012
ST Pharm Presents Phase 1 Clinical Trial Results of HIV Treatment Candidate at AIDS 2022
- STP0404 is the only clinical safety proven HIV treatment candidate with a novel mechanism that can block HIV re-activation. - STP0404 is expected to enter Phase 2a clinical trial in the US in 4Q 2022. SEOUL, South Korea, Aug. 3, 2022 /PRNewswire/ -- ST Pharm Co., Ltd. (237690:KOSDAQ) annou...
2022-08-03 20:00
1725
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
SUZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company completed the enrollment of 121 patients for its pha...
2022-08-03 19:38
1335
Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients
-- ASC10 is an oral double prodrug that is rapidly and completely converted in vivo into the active metabolite ASC10-A, which is the same active metabolite of molnupiravir -- Ascletis has filed multiple patent applications for ASC10 and its use globally. Compared with molnupiravir, ASC10 has a n...
2022-08-03 16:50
2110
Yidu Tech Releases FY2022 ESG Report, Using Socially Beneficial Technology to Drive the Sustainable Development of "Green Healthcare"
HONG KONG, Aug. 3, 2022 /PRNewswire/ -- The digital economy powered by innovative technologies such as artificial intelligence ("AI") and big data has become one of the most powerful drivers of economic growth since the COVID-19 outbreak, in keeping withChina's core strategy of "digitalization, ...
2022-08-03 15:09
1838
Ogawa World Berhad Won the Asia Pacific Enterprise Awards 2022 Malaysia under Inspirational Brand Category
KUALA LUMPUR, Malaysia, Aug. 3, 2022 /PRNewswire/ -- Enterprise Asia, the organizer of the 13th Asia Pacific Enterprise Awards (APEA) 2022 Malaysia, is pleased to recognize 47 exceptional business leaders and enterprises that have played a vital role in shapingMalaysia's entrepreneurial landscape...
2022-08-03 13:14
2869
Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma
* ATG-101 is a novel PD-L1/4-1BB bispecific antibody. It is Antengene's first in-house developed molecule with global rights. * ATG-101 demonstrates potent in vivo efficacy in anti-PD-1/PD-L1 resistant mouse tumor models. SHANGHAI and HONG KONG, Aug. 3, 2022 /PRNewswire/ -- Antengene Corpora...
2022-08-03 08:30
1869
Sanyou Biopharmaceuticals Closed the Series B+ Financing Round of Tens of Millions of RMB Led by Huatai Zijin
SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd. announced that it has closed the Series B+ financing round of tens of millions of RMB. In this round of financing led by Zijin Hongyun Fund and Huatai Guoxin Fund under Huatai Zijin, Sanyou also received follow-on investme...
2022-08-03 08:00
1615
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination
Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 PHILADELPHIA and FLORENCE, Italy, Aug. 2, 2022 /PRNewswire/ -- Context Therapeutics Inc. ("Context" or the "Company") (...
2022-08-02 22:49
2571
GenKOre develops hypercompact base editing system
DAEJEON, South Korea , Aug. 2, 2022 /PRNewswire/ -- GenKOre (homepage:
www.genkore.com
2022-08-02 22:44
1930
Gracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Aug. 2, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today a...
2022-08-02 21:00
1819
Metabolon Awarded ISO 9001:2015 Recertification
ISO 9001:2015 certificate re-issued to Metabolon following continued demonstrated ability to meet customer, statutory, and regulatory standards MORRISVILLE, N.C., Aug. 2, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance drug development and ...
2022-08-02 20:57
1592
CARsgen Appoints Dr. Hua Jiang as Executive Director
SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatDr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Direct...
2022-08-02 20:50
1939
Sironax Announces Closing of $200 Million Series B Financing
Financing from new and existing investors will support pipeline progression and expansion for age-related degenerative diseases BEIJING, Aug. 2, 2022 /PRNewswire/ -- Sironax, an emerging biotechnology company dedicated to the discovery and global development of novel treatments for patients with...
2022-08-02 19:00
1979
Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency
Implemented by the Centers for Disease Control and Prevention, the diagnosis code will accurately identify US patients with APDS, supporting care and research efforts LEIDEN, Netherlands, Aug. 2, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Na...
2022-08-02 13:00
2039
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 319 media titles]
2024-05-03 06:59
Shanghai Jiao Tong University Offers Free Online Courses for International Learners, Joint Programs with Tmall of Alibaba and Dow Gain High Popularity
[Picked up by 314 media titles]
2024-05-07 08:00
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 289 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 262 media titles]
2024-05-02 01:21
China-Serbia forum highlights community with shared future for mankind
[Picked up by 245 media titles]
2024-05-01 11:39
Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
12710
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
8818
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
8348
